Track record · closed signal

Stoke Therapeutics, Inc. (STOK) — closed signal from November 16, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on February 14, 2026.

Predicted vs. what happened

STOK price · publication thesis → realized outcomesplit-adjusted
$26.51 Published $34.46 Target $31.91 Window close $37.34 Peak
$25.50 – $27.10Entry zone — fair-value band
$26.51Published — price the day we called it
$34.46Target — the price the thesis aimed for
$37.34Peak — highest point inside the window, not a realized return
$31.91Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 24 days.

Peak price
$37.34
peak on January 7, 2026 — not a realized return
Peak gain
+40.9%
peak, from the publication price
Window close
$31.91
end-of-window price, context only
Days to target
24
Window
November 16, 2025 – February 14, 2026

The thesis — published November 16, 2025

Predicted growth
+30%
over the measurement window
Target price
$34.46
the price the thesis aimed for
Entry zone
$25.50 – $27.10
the fair-value band we waited for
Price at publication
$26.51
published November 16, 2025
Confidence
76%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Stoke looks appealing for a short-term biotech trade because interest is picking up and the company story is improving. Two research firms recently backed the stock, with one lifting 2025 expectations sharply and another keeping a $35 target. One trend signal is still weak, but upcoming updates on its lead drug could spark a move. If markets stay upbeat, we aim for continued gains over the next 0-3 months.

Primary drivers

  • Analysts raised ratings and lifted future estimates, supporting the share price
  • Investor mood is upbeat and the trading picture is getting better
  • Key drug zorevunersen has upcoming study news that could move shares
  • Biotech names often rise more when markets are stable and trending up

How it played out

STOK: target reached in 24 days

Lyra published STOK at 26.51 on 2025-11-16 for a short-term window ending 2026-02-14. The thesis expected 30% growth toward 34.46. It pointed to stronger analyst backing, better investor mood, upcoming zorevunersen study news, and a biotech setup that could benefit if markets stayed stable.

Inside the window, STOK reached the target. The stock peaked at 37.34 on 2026-01-07, with a 40.9% peak gain, and it reached the target in 24 days. It later ended the window at 31.91, below the peak but still above the publication price. The thesis played out.

What happened during the window

On 2025-12-16, Investor's Business Daily reported that Stoke had released third-quarter results on 2025-11-04, with revenue up 117% year over year to $10.6 million. The article also said the Biogen collaboration helped drive that revenue.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All STOK signals